Subsequently, our study demonstrated that inhibiting PLAAT4 could reverse the inhibitory effects of sh-CRABP2 on migration, invasion, and lipid metabolism, indicating that CRABP2 promotes NSCLC progression via regulating PLAAT4. This evidence concerns the gene CRABP2 and non-small cell lung carcinoma.